nodes	percent_of_prediction	percent_of_DWPC	metapath
Dobutamine—CA2—esophageal cancer	0.87	1	CbGaD
Dobutamine—Masoprocol—CYP19A1—esophageal cancer	0.00148	0.339	CrCbGaD
Dobutamine—Formoterol—CYP2A6—esophageal cancer	0.00144	0.331	CrCbGaD
Dobutamine—Arformoterol—CYP2A6—esophageal cancer	0.00144	0.331	CrCbGaD
Dobutamine—CA2—exocrine gland—esophageal cancer	0.00106	0.109	CbGeAlD
Dobutamine—Phlebitis—Carboplatin—esophageal cancer	0.00097	0.159	CcSEcCtD
Dobutamine—Skin necrosis—Cisplatin—esophageal cancer	0.000967	0.158	CcSEcCtD
Dobutamine—COMT—bronchus—esophageal cancer	0.00073	0.0754	CbGeAlD
Dobutamine—COMT—smooth muscle tissue—esophageal cancer	0.000715	0.0738	CbGeAlD
Dobutamine—CA2—neck—esophageal cancer	0.000677	0.07	CbGeAlD
Dobutamine—COMT—trachea—esophageal cancer	0.000656	0.0677	CbGeAlD
Dobutamine—ADRB1—bronchus—esophageal cancer	0.000619	0.0639	CbGeAlD
Dobutamine—COMT—digestive system—esophageal cancer	0.000564	0.0583	CbGeAlD
Dobutamine—Skin necrosis—Methotrexate—esophageal cancer	0.00053	0.0867	CcSEcCtD
Dobutamine—CA5B—lung—esophageal cancer	0.000512	0.0528	CbGeAlD
Dobutamine—COMT—lung—esophageal cancer	0.000471	0.0487	CbGeAlD
Dobutamine—CA2—epithelium—esophageal cancer	0.000461	0.0476	CbGeAlD
Dobutamine—CA2—bronchus—esophageal cancer	0.000454	0.0469	CbGeAlD
Dobutamine—CA2—smooth muscle tissue—esophageal cancer	0.000444	0.0459	CbGeAlD
Dobutamine—CA2—trachea—esophageal cancer	0.000407	0.0421	CbGeAlD
Dobutamine—ADRB1—lung—esophageal cancer	0.000399	0.0412	CbGeAlD
Dobutamine—CA2—digestive system—esophageal cancer	0.000351	0.0362	CbGeAlD
Dobutamine—CA5B—lymph node—esophageal cancer	0.00035	0.0361	CbGeAlD
Dobutamine—Skin exfoliation—Cisplatin—esophageal cancer	0.000322	0.0527	CcSEcCtD
Dobutamine—COMT—lymph node—esophageal cancer	0.000322	0.0333	CbGeAlD
Dobutamine—CA2—lung—esophageal cancer	0.000293	0.0302	CbGeAlD
Dobutamine—Phlebitis—Cisplatin—esophageal cancer	0.000285	0.0465	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.000276	0.045	CcSEcCtD
Dobutamine—Skin exfoliation—Capecitabine—esophageal cancer	0.000238	0.0388	CcSEcCtD
Dobutamine—Hypokalaemia—Cisplatin—esophageal cancer	0.000223	0.0365	CcSEcCtD
Dobutamine—Phlebitis—Capecitabine—esophageal cancer	0.00021	0.0343	CcSEcCtD
Dobutamine—CA2—lymph node—esophageal cancer	0.0002	0.0207	CbGeAlD
Dobutamine—ADRB2—Arf6 signaling events—EGFR—esophageal cancer	0.000191	0.00174	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ADH1B—esophageal cancer	0.000187	0.0017	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—TYMP—esophageal cancer	0.000179	0.00163	CbGpPWpGaD
Dobutamine—Skin exfoliation—Methotrexate—esophageal cancer	0.000177	0.0289	CcSEcCtD
Dobutamine—CA5B—Metabolism—ADH1B—esophageal cancer	0.000174	0.00159	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CYP26A1—esophageal cancer	0.000174	0.00158	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ALOX15—esophageal cancer	0.000169	0.00154	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—TYMP—esophageal cancer	0.000167	0.00152	CbGpPWpGaD
Dobutamine—CA2—Metabolism—SLC10A2—esophageal cancer	0.000166	0.00151	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CA1—esophageal cancer	0.000166	0.00151	CbGpPWpGaD
Dobutamine—Hypokalaemia—Capecitabine—esophageal cancer	0.000164	0.0269	CcSEcCtD
Dobutamine—COMT—Metabolism—SLC52A3—esophageal cancer	0.000163	0.00149	CbGpPWpGaD
Dobutamine—COMT—Metabolism—BLVRB—esophageal cancer	0.000163	0.00149	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CYP26A1—esophageal cancer	0.000162	0.00148	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—TPI1—esophageal cancer	0.000161	0.00147	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GSTO1—esophageal cancer	0.000161	0.00147	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ALOX15—esophageal cancer	0.000158	0.00144	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ALDOB—esophageal cancer	0.000155	0.00141	CbGpPWpGaD
Dobutamine—Angina pectoris—Capecitabine—esophageal cancer	0.000152	0.0249	CcSEcCtD
Dobutamine—CA5B—Metabolism—GSTO1—esophageal cancer	0.000151	0.00137	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—TPI1—esophageal cancer	0.000151	0.00137	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GAPDH—esophageal cancer	0.000149	0.00136	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CRABP1—esophageal cancer	0.000148	0.00135	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ALDOB—esophageal cancer	0.000145	0.00132	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ADH7—esophageal cancer	0.000141	0.00128	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PLCE1—esophageal cancer	0.000141	0.00128	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GNG7—esophageal cancer	0.00014	0.00128	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GAPDH—esophageal cancer	0.000139	0.00127	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CA1—esophageal cancer	0.000139	0.00127	CbGpPWpGaD
Dobutamine—COMT—Metabolism—SLC10A2—esophageal cancer	0.000139	0.00127	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CRABP1—esophageal cancer	0.000138	0.00126	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ALDH2—esophageal cancer	0.000132	0.0012	CbGpPWpGaD
Dobutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000131	0.0012	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GNG7—esophageal cancer	0.000131	0.0012	CbGpPWpGaD
Dobutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000128	0.00117	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CA2—esophageal cancer	0.000127	0.00116	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—GSTT1—esophageal cancer	0.000125	0.00114	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CYP2A6—esophageal cancer	0.000124	0.00113	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ADH1B—esophageal cancer	0.000124	0.00113	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ALDH2—esophageal cancer	0.000123	0.00112	CbGpPWpGaD
Dobutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000122	0.00111	CbGpPWpGaD
Dobutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000119	0.00109	CbGpPWpGaD
Dobutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000119	0.00108	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ADH7—esophageal cancer	0.000118	0.00108	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PLCE1—esophageal cancer	0.000118	0.00108	CbGpPWpGaD
Dobutamine—CA2—Metabolism—TYMP—esophageal cancer	0.000118	0.00108	CbGpPWpGaD
Dobutamine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000118	0.0193	CcSEcCtD
Dobutamine—Tachycardia—Cisplatin—esophageal cancer	0.000118	0.0192	CcSEcCtD
Dobutamine—CA5A—Metabolism—PTGS1—esophageal cancer	0.000117	0.00107	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ENO1—esophageal cancer	0.000117	0.00107	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—GSTT1—esophageal cancer	0.000117	0.00107	CbGpPWpGaD
Dobutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000116	0.00106	CbGpPWpGaD
Dobutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000116	0.00106	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PSME1—esophageal cancer	0.000116	0.00105	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PSME2—esophageal cancer	0.000116	0.00105	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CYP2A6—esophageal cancer	0.000116	0.00105	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CYP26A1—esophageal cancer	0.000115	0.00105	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000114	0.00104	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—GNG7—esophageal cancer	0.000114	0.00103	CbGpPWpGaD
Dobutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000113	0.00103	CbGpPWpGaD
Dobutamine—Hypotension—Cisplatin—esophageal cancer	0.000113	0.0184	CcSEcCtD
Dobutamine—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000112	0.00102	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ALOX15—esophageal cancer	0.000112	0.00102	CbGpPWpGaD
Dobutamine—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	0.000111	0.00101	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ENO1—esophageal cancer	0.00011	0.000999	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PTGS1—esophageal cancer	0.00011	0.000999	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PSME2—esophageal cancer	0.000108	0.000984	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PSME1—esophageal cancer	0.000108	0.000984	CbGpPWpGaD
Dobutamine—Dyspnoea—Cisplatin—esophageal cancer	0.000107	0.0176	CcSEcCtD
Dobutamine—CA2—Metabolism—TPI1—esophageal cancer	0.000107	0.000974	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GSTO1—esophageal cancer	0.000107	0.000974	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000104	0.000947	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ADH1B—esophageal cancer	0.000104	0.000944	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ALDOB—esophageal cancer	0.000102	0.000933	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000102	0.000927	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—CXCL2—esophageal cancer	0.0001	0.000912	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CYP1B1—esophageal cancer	9.98e-05	0.00091	CbGpPWpGaD
Dobutamine—COMT—Metabolism—TYMP—esophageal cancer	9.89e-05	0.000902	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GAPDH—esophageal cancer	9.85e-05	0.000898	CbGpPWpGaD
Dobutamine—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	9.78e-05	0.000892	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CRABP1—esophageal cancer	9.77e-05	0.00089	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CYP26A1—esophageal cancer	9.62e-05	0.000878	CbGpPWpGaD
Dobutamine—Palpitations—Capecitabine—esophageal cancer	9.62e-05	0.0157	CcSEcCtD
Dobutamine—ADRB1—Signaling Pathways—GDI2—esophageal cancer	9.53e-05	0.000868	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ALOX15—esophageal cancer	9.38e-05	0.000855	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CYP19A1—esophageal cancer	9.38e-05	0.000855	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GDI2—esophageal cancer	9.32e-05	0.00085	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CYP1B1—esophageal cancer	9.31e-05	0.000849	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—ANXA1—esophageal cancer	9.3e-05	0.000848	CbGpPWpGaD
Dobutamine—CA2—Metabolism—GNG7—esophageal cancer	9.29e-05	0.000847	CbGpPWpGaD
Dobutamine—Chest pain—Capecitabine—esophageal cancer	9.27e-05	0.0151	CcSEcCtD
Dobutamine—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	9.09e-05	0.000829	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—SST—esophageal cancer	9.04e-05	0.000825	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GSTO1—esophageal cancer	8.95e-05	0.000816	CbGpPWpGaD
Dobutamine—COMT—Metabolism—TPI1—esophageal cancer	8.95e-05	0.000816	CbGpPWpGaD
Dobutamine—ADRB2—GPCR ligand binding—SST—esophageal cancer	8.85e-05	0.000807	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—GHRL—esophageal cancer	8.81e-05	0.000804	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CYP19A1—esophageal cancer	8.76e-05	0.000798	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ALDH2—esophageal cancer	8.7e-05	0.000794	CbGpPWpGaD
Dobutamine—Thrombocytopenia—Capecitabine—esophageal cancer	8.7e-05	0.0142	CcSEcCtD
Dobutamine—Tachycardia—Capecitabine—esophageal cancer	8.67e-05	0.0142	CcSEcCtD
Dobutamine—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	8.62e-05	0.000786	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ALDOB—esophageal cancer	8.58e-05	0.000782	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—HMOX1—esophageal cancer	8.56e-05	0.00078	CbGpPWpGaD
Dobutamine—Hypotension—Capecitabine—esophageal cancer	8.3e-05	0.0136	CcSEcCtD
Dobutamine—CA2—Metabolism—GSTT1—esophageal cancer	8.28e-05	0.000755	CbGpPWpGaD
Dobutamine—COMT—Metabolism—GAPDH—esophageal cancer	8.26e-05	0.000753	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—ABCB1—esophageal cancer	8.22e-05	0.000749	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CRABP1—esophageal cancer	8.18e-05	0.000746	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CYP2A6—esophageal cancer	8.18e-05	0.000746	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—HMOX1—esophageal cancer	7.99e-05	0.000729	CbGpPWpGaD
Dobutamine—Dyspnoea—Capecitabine—esophageal cancer	7.92e-05	0.0129	CcSEcCtD
Dobutamine—COMT—Metabolism—GNG7—esophageal cancer	7.78e-05	0.00071	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ENO1—esophageal cancer	7.76e-05	0.000707	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTGS1—esophageal cancer	7.76e-05	0.000707	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—ABCB1—esophageal cancer	7.67e-05	0.000699	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PSME1—esophageal cancer	7.64e-05	0.000697	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PSME2—esophageal cancer	7.64e-05	0.000697	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—AKAP13—esophageal cancer	7.37e-05	0.000672	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ALDH2—esophageal cancer	7.29e-05	0.000665	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	7.21e-05	0.000658	CbGpPWpGaD
Dobutamine—Nausea—Cisplatin—esophageal cancer	7.16e-05	0.0117	CcSEcCtD
Dobutamine—COMT—Metabolism—GSTT1—esophageal cancer	6.94e-05	0.000633	CbGpPWpGaD
Dobutamine—Chest pain—Methotrexate—esophageal cancer	6.9e-05	0.0113	CcSEcCtD
Dobutamine—ADRB1—Signaling Pathways—KMT2D—esophageal cancer	6.89e-05	0.000628	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CYP2A6—esophageal cancer	6.86e-05	0.000625	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PDE4D—esophageal cancer	6.74e-05	0.000615	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	6.74e-05	0.000614	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—AKAP13—esophageal cancer	6.7e-05	0.00061	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	6.6e-05	0.000601	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CYP1B1—esophageal cancer	6.6e-05	0.000601	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	6.55e-05	0.000597	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTGS1—esophageal cancer	6.5e-05	0.000593	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ENO1—esophageal cancer	6.5e-05	0.000593	CbGpPWpGaD
Dobutamine—Thrombocytopenia—Methotrexate—esophageal cancer	6.47e-05	0.0106	CcSEcCtD
Dobutamine—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	6.41e-05	0.000585	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PSME2—esophageal cancer	6.41e-05	0.000584	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PSME1—esophageal cancer	6.41e-05	0.000584	CbGpPWpGaD
Dobutamine—Pruritus—Capecitabine—esophageal cancer	6.29e-05	0.0103	CcSEcCtD
Dobutamine—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	6.27e-05	0.000572	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CYP19A1—esophageal cancer	6.2e-05	0.000565	CbGpPWpGaD
Dobutamine—Hypotension—Methotrexate—esophageal cancer	6.18e-05	0.0101	CcSEcCtD
Dobutamine—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	6.14e-05	0.00056	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	6.12e-05	0.000558	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	6e-05	0.000547	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	5.99e-05	0.000546	CbGpPWpGaD
Dobutamine—Dyspnoea—Methotrexate—esophageal cancer	5.9e-05	0.00963	CcSEcCtD
Dobutamine—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	5.82e-05	0.000531	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	5.7e-05	0.00052	CbGpPWpGaD
Dobutamine—CA2—Metabolism—HMOX1—esophageal cancer	5.66e-05	0.000516	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	5.65e-05	0.000515	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—WWOX—esophageal cancer	5.61e-05	0.000512	CbGpPWpGaD
Dobutamine—Headache—Capecitabine—esophageal cancer	5.57e-05	0.00909	CcSEcCtD
Dobutamine—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	5.53e-05	0.000504	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CYP1B1—esophageal cancer	5.53e-05	0.000504	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—WWOX—esophageal cancer	5.49e-05	0.000501	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—CREBBP—esophageal cancer	5.49e-05	0.000501	CbGpPWpGaD
Dobutamine—CA2—Metabolism—ABCB1—esophageal cancer	5.43e-05	0.000495	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	5.34e-05	0.000487	CbGpPWpGaD
Dobutamine—Nausea—Capecitabine—esophageal cancer	5.28e-05	0.00862	CcSEcCtD
Dobutamine—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	5.25e-05	0.000479	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	5.22e-05	0.000476	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—WIF1—esophageal cancer	5.22e-05	0.000476	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CYP19A1—esophageal cancer	5.2e-05	0.000474	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	5.14e-05	0.000469	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	5.13e-05	0.000468	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—CREBBP—esophageal cancer	5.13e-05	0.000467	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—SST—esophageal cancer	5.11e-05	0.000466	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—WIF1—esophageal cancer	5.11e-05	0.000465	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	5.02e-05	0.000458	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—SST—esophageal cancer	5e-05	0.000456	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	4.98e-05	0.000454	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—NOS3—esophageal cancer	4.92e-05	0.000448	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	4.87e-05	0.000444	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	4.82e-05	0.000439	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	4.77e-05	0.000435	CbGpPWpGaD
Dobutamine—COMT—Metabolism—HMOX1—esophageal cancer	4.74e-05	0.000432	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	4.71e-05	0.00043	CbGpPWpGaD
Dobutamine—Pruritus—Methotrexate—esophageal cancer	4.68e-05	0.00765	CcSEcCtD
Dobutamine—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	4.67e-05	0.000426	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—SST—esophageal cancer	4.64e-05	0.000423	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—NOS3—esophageal cancer	4.59e-05	0.000418	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ABCB1—esophageal cancer	4.55e-05	0.000415	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—SST—esophageal cancer	4.54e-05	0.000414	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	4.52e-05	0.000412	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PFN1—esophageal cancer	4.51e-05	0.000411	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PTGS2—esophageal cancer	4.5e-05	0.00041	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	4.42e-05	0.000403	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PFN1—esophageal cancer	4.41e-05	0.000402	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PTGS2—esophageal cancer	4.2e-05	0.000383	CbGpPWpGaD
Dobutamine—Headache—Methotrexate—esophageal cancer	4.14e-05	0.00677	CcSEcCtD
Dobutamine—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	4.05e-05	0.000369	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	3.96e-05	0.000361	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	3.96e-05	0.000361	CbGpPWpGaD
Dobutamine—Nausea—Methotrexate—esophageal cancer	3.93e-05	0.00642	CcSEcCtD
Dobutamine—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	3.87e-05	0.000353	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—EP300—esophageal cancer	3.74e-05	0.000341	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	3.65e-05	0.000333	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CREBBP—esophageal cancer	3.63e-05	0.000331	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	3.62e-05	0.00033	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	3.57e-05	0.000326	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	3.54e-05	0.000323	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—EP300—esophageal cancer	3.49e-05	0.000318	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GNG7—esophageal cancer	3.44e-05	0.000314	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GNG7—esophageal cancer	3.37e-05	0.000307	CbGpPWpGaD
Dobutamine—CA2—Metabolism—NOS3—esophageal cancer	3.25e-05	0.000296	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—XIAP—esophageal cancer	3.22e-05	0.000294	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—XIAP—esophageal cancer	3.15e-05	0.000288	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	3.05e-05	0.000278	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CREBBP—esophageal cancer	3.04e-05	0.000277	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	3.03e-05	0.000276	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	2.98e-05	0.000272	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTGS2—esophageal cancer	2.97e-05	0.000271	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	2.97e-05	0.00027	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PSME1—esophageal cancer	2.83e-05	0.000258	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PSME2—esophageal cancer	2.83e-05	0.000258	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	2.82e-05	0.000257	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PSME2—esophageal cancer	2.77e-05	0.000253	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PSME1—esophageal cancer	2.77e-05	0.000253	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PIK3CA—esophageal cancer	2.77e-05	0.000252	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	2.76e-05	0.000251	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SST—esophageal cancer	2.74e-05	0.00025	CbGpPWpGaD
Dobutamine—COMT—Metabolism—NOS3—esophageal cancer	2.72e-05	0.000248	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SST—esophageal cancer	2.68e-05	0.000245	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	2.67e-05	0.000244	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GHRL—esophageal cancer	2.67e-05	0.000244	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	2.63e-05	0.00024	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GHRL—esophageal cancer	2.61e-05	0.000238	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	2.61e-05	0.000238	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PIK3CA—esophageal cancer	2.58e-05	0.000235	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	2.57e-05	0.000234	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTGS2—esophageal cancer	2.49e-05	0.000227	CbGpPWpGaD
Dobutamine—CA2—Metabolism—EP300—esophageal cancer	2.47e-05	0.000225	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	2.4e-05	0.000218	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	2.34e-05	0.000214	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	2.13e-05	0.000194	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	2.08e-05	0.00019	CbGpPWpGaD
Dobutamine—COMT—Metabolism—EP300—esophageal cancer	2.07e-05	0.000189	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	2.01e-05	0.000183	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	1.97e-05	0.000179	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CA—esophageal cancer	1.83e-05	0.000167	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	1.65e-05	0.00015	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	1.61e-05	0.000147	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KDR—esophageal cancer	1.57e-05	0.000144	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KDR—esophageal cancer	1.54e-05	0.00014	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CA—esophageal cancer	1.53e-05	0.00014	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	1.48e-05	0.000135	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	1.45e-05	0.000132	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	1.34e-05	0.000123	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	1.32e-05	0.00012	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	1.32e-05	0.00012	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	1.29e-05	0.000118	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.24e-05	0.000113	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NOS3—esophageal cancer	1.2e-05	0.00011	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NOS3—esophageal cancer	1.18e-05	0.000107	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	1.15e-05	0.000105	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	1.13e-05	0.000103	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	1.12e-05	0.000102	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	1.1e-05	0.0001	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CCND1—esophageal cancer	9.95e-06	9.07e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CCND1—esophageal cancer	9.73e-06	8.88e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	9.63e-06	8.78e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	9.42e-06	8.59e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EP300—esophageal cancer	9.16e-06	8.35e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EP300—esophageal cancer	8.96e-06	8.17e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MYC—esophageal cancer	7.98e-06	7.28e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MYC—esophageal cancer	7.81e-06	7.12e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EGFR—esophageal cancer	7.81e-06	7.12e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EGFR—esophageal cancer	7.64e-06	6.96e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	6.78e-06	6.18e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	6.63e-06	6.04e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TP53—esophageal cancer	6.55e-06	5.98e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TP53—esophageal cancer	6.41e-06	5.85e-05	CbGpPWpGaD
